ZBIO:NSD-Zenas BioPharma, Inc. Common Stock (USD)

COMMON STOCK | Trading--Inverse Equity |

Last Closing

USD 19

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

N/A

USD 2.57B
BIS ProShares UltraShort Nasdaq Bi..

N/A

USD 3.21M

ETFs Containing ZBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 89.62% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.62% 100% F 92% A
Trailing 5 Years  
Capital Gain 29.96% 100% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.96% 100% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain -0.77% 33% F 41% F
Dividend Return -0.77% 33% F 37% F
Total Return 0.00% 33% F N/A F
Risk Return Profile  
Volatility (Standard Deviation) 8.51% 100% F 89% A-
Risk Adjusted Return -9.04% 33% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.